Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02157324 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Acalabrutinib in Combination With ACP-319, for Treatment of Chronic Lymphocytic Leukemia

StatusActive, Not Recruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. 4 versions Re-verified since Oct 28, 2024, no change to tracked fieldsv26-v29
  2. Completion date: May 31, 2026 to Apr 1, 2026v25
  3. 3 versions Re-verified since Nov 6, 2023, no change to tracked fieldsv22-v24
  4. Completion date: Dec 31, 2025 to May 31, 2026v21
  5. 3 versions Re-verified since Aug 25, 2022, no change to tracked fieldsv18-v20
Show 16 earlier versionsHide 16 earlier versions
  1. Study sites: 2 to 3v17
  2. Site details revised at 2 of 2 sitesv16
  3. Re-verified, no change to tracked fieldsv15
  4. Site details revised at 2 of 2 sitesv14
  5. Primary endpoint revised Primary completion date changed from estimate of Jul 2020 to Jul 20, 2020 · Completion date: Dec 31, 2025 · Start date: Aug 2014 to Aug 18, 2014 · 2 morev13 Show 5 more changesShow less
    • Primary completion date changed from estimate of Jul 2020 to Jul 20, 2020
    • Completion date: Dec 31, 2025
    • Start date: Aug 2014 to Aug 18, 2014
    • Secondary endpoints expanded, about 30 words
    • Study sites revised (2)

    See this version in full on ClinicalTrials.gov ↗

  6. Primary completion date: Sep 2018 to Jul 2020v12
  7. Re-verified, no change to tracked fieldsv11
  8. Primary endpoint revised Enrollment target: estimated 48 to confirmed 12 · Interventions: ACP-196 and ACP-319 (Drug) to ACP-319 (Drug), acalabrutinib (Drug) · Eligibility criteria revised · 2 morev10 Show 5 more changesShow less
    • Enrollment target: estimated 48 to confirmed 12
    • Interventions: ACP-196 and ACP-319 (Drug) to ACP-319 (Drug), acalabrutinib (Drug)
    • Eligibility criteria revised
    • Study title revised
    • Study arms: 1 to 2

    See this version in full on ClinicalTrials.gov ↗

  9. Primary completion date: Aug 2017 to Sep 2018 Trial status: Recruiting to Active, Not Recruiting · Study sites: 3 to 2 · Eligibility criteria revisedv9 Show 3 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Study sites: 3 to 2
    • Eligibility criteria revised

    See this version in full on ClinicalTrials.gov ↗

  10. Study sites: 2 to 3 Interventions: ACP-196 and ACP-319 (Drug), ACP-319 and ACP-196 (Drug) to ACP-196 and ACP-319 (Drug) · Study arms: 2 to 1v8 Show 2 more changesShow less
    • Interventions: ACP-196 and ACP-319 (Drug), ACP-319 and ACP-196 (Drug) to ACP-196 and ACP-319 (Drug)
    • Study arms: 2 to 1
  11. Enrollment target: 12 to 48v7
  12. 2 versions Re-verified since Sep 17, 2014, no change to tracked fieldsv5-v6
  13. Study sites: 1 to 2v4
  14. Trial status: Not Yet Recruiting to Recruiting Primary completion date: Aug 2015 to Aug 2017 · Start date: Jun 2014 to Aug 2014 · Study site revisedv3 Show 3 more changesShow less
    • Primary completion date: Aug 2015 to Aug 2017
    • Start date: Jun 2014 to Aug 2014
    • Study site revised

    See this version in full on ClinicalTrials.gov ↗

  15. Study sites: 0 to 1v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is evaluating the safety and efficacy of the combined use of acalabrutinib and ACP-319, for the treatment of chronic lymphocytic leukemia (CLL)
Trial Details
NCT Number NCT02157324
Lead Sponsor Acerta Pharma BV
Conditions Chronic Lymphocytic Leukemia
Enrollment 12 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov